Milestone Pharmaceuticals Inc. (MIST)
NASDAQ: MIST · Real-Time Price · USD
1.850
-0.010 (-0.54%)
At close: Apr 28, 2026, 4:00 PM EDT
1.880
+0.030 (1.62%)
After-hours: Apr 28, 2026, 7:36 PM EDT
Milestone Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 1.55 | - | 1 | 5 | 15 | |
| Revenue Growth (YoY) | - | - | -80.00% | -66.67% | - | |
| Gross Profit | 1.55 | - | 1 | 5 | 15 | |
| Selling, General & Admin | 45.58 | 27.75 | 31.05 | 24.81 | 19.4 | |
| Research & Development | 18.11 | 14.36 | 31.05 | 39.83 | 38.67 | |
| Operating Expenses | 63.69 | 42.1 | 62.1 | 64.64 | 58.07 | |
| Operating Income | -62.14 | -42.1 | -61.1 | -59.64 | -43.07 | |
| Interest Expense | -3.84 | -3.58 | -2.55 | - | - | |
| Interest & Investment Income | 2.92 | 4.16 | 3.97 | 1.25 | 0.22 | |
| Pretax Income | -63.06 | -41.52 | -59.69 | -58.39 | -42.85 | |
| Net Income | -63.06 | -41.52 | -59.69 | -58.39 | -42.85 | |
| Net Income to Common | -63.06 | -41.52 | -59.69 | -58.39 | -42.85 | |
| Shares Outstanding (Basic) | 84 | 62 | 43 | 42 | 42 | |
| Shares Outstanding (Diluted) | 84 | 62 | 43 | 42 | 42 | |
| Shares Change (YoY) | 34.84% | 44.82% | 1.19% | 1.47% | 42.56% | |
| EPS (Basic) | -0.75 | -0.67 | -1.39 | -1.38 | -1.02 | |
| EPS (Diluted) | -0.75 | -0.67 | -1.39 | -1.38 | -1.02 | |
| Free Cash Flow | -49.34 | -28.88 | -46.54 | -52.74 | -33.22 | |
| Free Cash Flow Per Share | -0.59 | -0.46 | -1.08 | -1.24 | -0.79 | |
| Gross Margin | 100.00% | - | 100.00% | 100.00% | 100.00% | |
| Operating Margin | -4019.40% | - | -6109.80% | -1192.84% | -287.15% | |
| Profit Margin | -4078.78% | - | -5968.50% | -1167.76% | -285.69% | |
| Free Cash Flow Margin | -3191.66% | - | -4653.60% | -1054.82% | -221.49% | |
| EBITDA | -62.03 | -42 | -61.01 | -59.55 | -42.98 | |
| EBITDA Margin | - | - | - | - | -286.53% | |
| D&A For EBITDA | 0.11 | 0.11 | 0.09 | 0.09 | 0.09 | |
| EBIT | -62.14 | -42.1 | -61.1 | -59.64 | -43.07 | |
| EBIT Margin | - | - | - | - | -287.15% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.